Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 +5.00%12 Return-on-Tangible-Equity is 22.53% as of Mar. 2026, which is 87% above its 10-year median of 12.04. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 896 Drug Manufacturers companies, Astonea Labs ranks worse than 51.12% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Astonea Labs's annualized net income for the quarter that ended in Mar. 2026 was ₹123.9 Mil. Astonea Labs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹550.0 Mil. Therefore, Astonea Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 22.53%.
The historical rank and industry rank for Astonea Labs's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544409'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.33 Med: 12.04 Max: 40.48
Current: 7.25
During the past 5 years, Astonea Labs's highest Return-on-Tangible-Equity was 40.48%. The lowest was 3.33%. And the median was 12.04%.
BOM:544409's Return-on-Tangible-Equity is ranked worse than 51.12% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.645
vs BOM:544409: 7.25
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Astonea Labs Return-on-Tangible-Equity Related Terms
Astonea Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Astonea Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544409 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Astonea Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 22.53% mean?
Astonea Labs (BOM:544409) has a Return-on-Tangible-Equity of 22.53% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astonea Labs and its competitors. This is 87% above median its historical median of 12.04. Over the past decade, Astonea Labs' Return-on-Tangible-Equity has ranged from 3.33 to 40.48. According to the industry distribution chart, Astonea Labs ranks #458 out of 896 companies in the Drug Manufacturers industry, placing it in the top 51.1%.
Is Astonea Labs' Return-on-Tangible-Equity too high?
Astonea Labs' current Return-on-Tangible-Equity of 22.53% is 87% above median its 10-year median of 12.04. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 40.48. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.65. Astonea Labs' value of 22.53% is 194.7% above this industry median. Based on the distribution chart, Astonea Labs ranks #458 out of 896 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #458 out of 896 companies for Return-on-Tangible-Equity. This places Astonea Labs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.65. Astonea Labs' value of 22.53% is 194.7% above this benchmark. Historically, Astonea Labs' own Return-on-Tangible-Equity has ranged from 3.33 to 40.48 over the past decade. While the company's 10-year median is 12.04 vs. the industry median of 7.65, Astonea Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.65, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astonea Labs's current Return-on-Tangible-Equity of 22.53% is 194.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current Return-on-Tangible-Equity is 22.53%, which is 87% above median its own 10-year median of 12.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current Return-on-Tangible-Equity of 22.53%. The current Return-on-Tangible-Equity is 22.53%, which is 87% above median its 10-year median of 12.04 and 194.7% above the Drug Manufacturers industry median of 7.65. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current Return-on-Tangible-Equity is 22.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
